{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T21:57:10Z","timestamp":1782597430420,"version":"3.54.5"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Federal Joint Committee in Germany","award":["01VSF16020"],"award-info":[{"award-number":["01VSF16020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Atrial fibrillation (AF) is a risk factor for brain infarction, which can lead to epilepsy. We aimed to investigate whether treatment of AF with direct oral anticoagulants (DOACs) affects the risk of epilepsy in comparison to treatment with the vitamin K antagonist phenprocoumon (PPC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We performed an active comparator, nested case-control study based on the German Pharmacoepidemiological Research Database that includes claims data from statutory health insurance providers of about 25 million persons since 2004. In 2011\u201317, 227 707 AF patients initiated treatment with a DOAC or PPC, of which 1828 cases developed epilepsy on current treatment with an oral anticoagulant. They were matched to 19 084 controls without epilepsy. Patients with DOAC treatment for AF had an overall higher risk of epilepsy with an odds ratio of 1.39, 95% CI (1.24; 1.55) compared to current PPC treatment. Cases had higher baseline CHA2DS2-VASc scores and more frequently a history of stroke than controls. After excluding patients with ischaemic stroke prior to the diagnosis of epilepsy, the risk of epilepsy was still higher on DOACs than on PPC. In contrast, within a cohort of patients with venous thromboembolism, the risk of epilepsy on treatment with DOACs was less elevated [adjusted odds ratio 1.15, 95% CI (0.98; 1.34)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with AF initiating oral anticoagulation, treatment with a DOAC was associated with an increased risk of epilepsy compared to the vitamin K antagonist PPC. Covert brain infarction may explain the observed elevated risk of epilepsy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euad087","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T08:11:58Z","timestamp":1680595918000},"source":"Crossref","is-referenced-by-count":7,"title":["In atrial fibrillation epilepsy risk differs between oral anticoagulants: active comparator, nested case-control study"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-7978","authenticated-orcid":false,"given":"Katharina","family":"Platzbecker","sequence":"first","affiliation":[{"name":"Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS , Achterstra\u00dfe 30, 28359 Bremen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-4426","authenticated-orcid":false,"given":"Helge","family":"M\u00fcller-Fielitz","sequence":"additional","affiliation":[{"name":"Institute for Experimental and Clinical Pharmacology and Toxicology, University of L\u00fcbeck , Ratzeburger Allee 160, 23562 L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2216-6653","authenticated-orcid":false,"given":"Ronja","family":"Foraita","sequence":"additional","affiliation":[{"name":"Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS , Achterstra\u00dfe 30, 28359 Bremen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8000","authenticated-orcid":false,"given":"Matthias J","family":"Koepp","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology , Queen Square, Box 29, London WC1N 3BG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8109-1108","authenticated-orcid":false,"given":"Annemarie","family":"Voss","sequence":"additional","affiliation":[{"name":"Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS , Achterstra\u00dfe 30, 28359 Bremen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-0902","authenticated-orcid":false,"given":"Ren\u00e9","family":"Pflock","sequence":"additional","affiliation":[{"name":"Institute for Experimental and Clinical Pharmacology and Toxicology, University of L\u00fcbeck , Ratzeburger Allee 160, 23562 L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-3331","authenticated-orcid":false,"given":"Roland","family":"Linder","sequence":"additional","affiliation":[{"name":"Techniker Krankenkasse , Bramfelder Stra\u00dfe 140, 22305 Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-0726","authenticated-orcid":false,"given":"Iris","family":"Pigeot","sequence":"additional","affiliation":[{"name":"Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS , Achterstra\u00dfe 30, 28359 Bremen , Germany"},{"name":"Faculty of Mathematics and Computer Science, University of Bremen , Bibliothekstra\u00dfe 5, 28334 Bremen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-1866","authenticated-orcid":false,"given":"Tania","family":"Schink","sequence":"additional","affiliation":[{"name":"Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS , Achterstra\u00dfe 30, 28359 Bremen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-9718","authenticated-orcid":false,"given":"Markus","family":"Schwaninger","sequence":"additional","affiliation":[{"name":"Institute for Experimental and Clinical Pharmacology and Toxicology, University of L\u00fcbeck , Ratzeburger Allee 160, 23562 L\u00fcbeck , Germany"},{"name":"DZHK (German Research Centre for Cardiovascular Research) , Hamburg-L\u00fcbeck-Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"2023053014524723000_euad087-B1","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Lopez-Lopez","year":"2017","journal-title":"BMJ"},{"key":"2023053014524723000_euad087-B2","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova","year":"2018","journal-title":"BMJ"},{"key":"2023053014524723000_euad087-B3","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1161\/STROKEAHA.120.030686","article-title":"Covert brain infarction: towards precision medicine in research, diagnosis, and therapy for a silent pandemic","volume":"51","author":"Meinel","year":"2020","journal-title":"Stroke"},{"key":"2023053014524723000_euad087-B4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.STR.19.8.955","article-title":"Asymptomatic cerebral infarction in patients with chronic atrial fibrillation","volume":"19","author":"Kempster","year":"1988","journal-title":"Stroke"},{"key":"2023053014524723000_euad087-B5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clineuro.2012.07.009","article-title":"Prevalence and subtypes of radiological cerebrovascular disease in late-onset isolated seizures and epilepsy","volume":"115","author":"Maxwell","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"2023053014524723000_euad087-B6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jacc.2018.12.039","article-title":"Relationships of overt and silent brain lesions with cognitive function in patients with atrial fibrillation","volume":"73","author":"Conen","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023053014524723000_euad087-B7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1474-4422(09)70240-6","article-title":"Epilepsy in later life","volume":"8","author":"Brodie","year":"2009","journal-title":"Lancet Neurol"},{"key":"2023053014524723000_euad087-B8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1474-4422(17)30404-0","article-title":"Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study","volume":"17","author":"Galovic","year":"2018","journal-title":"Lancet Neurol"},{"key":"2023053014524723000_euad087-B9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.amjcard.2016.07.063","article-title":"Usefulness of the CHADS2 score for determining risk of seizure in patients with atrial fibrillation","volume":"118","author":"Hsu","year":"2016","journal-title":"Am J Cardiol"},{"key":"2023053014524723000_euad087-B10","doi-asserted-by":"crossref","first-page":"108721","DOI":"10.1016\/j.yebeh.2022.108721","article-title":"Atrial fibrillation is associated with a subsequent epilepsy diagnosis independent of stroke: a retrospective matched administrative cohort study on 149,632 patients","volume":"132","author":"Doege","year":"2022","journal-title":"Epilepsy Behav"},{"key":"2023053014524723000_euad087-B11","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.120.049768","article-title":"Stroke prevention in atrial fibrillation: looking forward","volume":"142","author":"Katsanos","year":"2020","journal-title":"Circulation"},{"key":"2023053014524723000_euad087-B12","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac020","article-title":"Silent brain infarcts impact on cognitive function in atrial fibrillation","author":"Kuhne","year":"2022","journal-title":"Eur Heart J"},{"key":"2023053014524723000_euad087-B13","article-title":"A discovery and verification approach for pharmacovigilance using electronic health care data","author":"Dijkstra","year":"2022","journal-title":"medRxiv"},{"key":"2023053014524723000_euad087-B14","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/europace\/euab091","article-title":"Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries","volume":"23","author":"Komen","year":"2021","journal-title":"Europace"},{"key":"2023053014524723000_euad087-B15","volume-title":"Modern epidemiology","author":"Rothman","year":"2008","edition":"3rd ed"},{"key":"2023053014524723000_euad087-B16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug-drug interactions: important determinants of drug disposition and effects","volume":"65","author":"K\u00f6nig","year":"2013","journal-title":"Pharmacol Rev"},{"key":"2023053014524723000_euad087-B17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fncel.2013.00019","article-title":"Treating seizures and epilepsy with anticoagulants?","volume":"7","author":"Maggio","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"2023053014524723000_euad087-B18","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2023053014524723000_euad087-B19","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/europace\/euw191","article-title":"Incidence of silent cerebral infarctions after catheter ablation of atrial fibrillation utilizing the second-generation cryoballoon","volume":"19","author":"Nakamura","year":"2017","journal-title":"Europace"},{"key":"2023053014524723000_euad087-B20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/europace\/euz291","article-title":"Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP atrial fibrillation ablation long-term and atrial fibrillation general pilot registries","volume":"22","author":"Tilz","year":"2020","journal-title":"Europace"},{"key":"2023053014524723000_euad087-B21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ahj.2016.05.007","article-title":"Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)","volume":"178","author":"Lip","year":"2016","journal-title":"Am Heart J"},{"key":"2023053014524723000_euad087-B22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1747493018784478","article-title":"Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial","volume":"14","author":"Sharma","year":"2019","journal-title":"Int J Stroke"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/5\/euad087\/50487619\/euad087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/5\/euad087\/50487619\/euad087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T14:53:22Z","timestamp":1685458402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad087\/7101281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad087","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,4,4]]},"article-number":"euad087"}}